• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1210388 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- V; G/ s9 K4 t' `4 x; |9 X# m& `/ T; m
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * Y* j! l3 _: `& E( i" i
+ Author Affiliations  J8 s4 U/ f" B3 R9 _* @

" G" k# U; Q0 O1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
: o8 y! d& e$ a7 }2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 P# S2 Y: a- @: e; U; ?3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) ]- r4 T% h: o
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . o* H- F  U, Q- @" n" B$ E
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
, ]  c( E. j; Z( S6 k! ^9 A: {1 P6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : E5 _1 i: k4 S9 }& r. t6 k
7Kinki University School of Medicine, Osaka 589-8511, Japan $ w% b% e. A$ e) b* ?
8Izumi Municipal Hospital, Osaka 594-0071, Japan * ]; u% X; Z% j; @* R
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
1 x; \0 o& `( J6 Q8 {Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 1 W& _% a2 o. r% y5 i
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
  o. {3 v1 z: W: O$ \% \! U
. i' C  ?/ }$ P% P  c. \- E
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type # \+ x3 ^3 W6 m0 N/ x# k) a

  n+ O" b+ x* r9 b9 w) BAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 1 [2 e: x- A5 y' d* V9 m
9 |# Z3 X3 ?/ r( f: z+ H
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
3 A" T- z' i; T) W
8 O' i1 h7 s$ @5 ~( A5 a0 dPublished online on: Thursday, December 1, 2011 ) b2 C) P% a0 x9 t

. R+ R3 |, _9 QDoi: 10.3892/ol.2011.507 7 h( Z3 j6 L2 T& D) ]

  ~" c) N8 q" T6 \Pages: 405-410
/ v: I% D: o! J) C8 j3 l4 x, r. V: R" I2 z; h
Abstract:2 q) K. A' _4 Q8 D0 o
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
/ F9 c5 U* a& N8 E; n/ I$ x ! ~) u0 g9 Q0 f7 P2 M
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population9 h% b: l, a, {6 b
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 + |  P  U2 w& ~  u6 N% O# ~1 I
+ Author Affiliations
$ H% c7 x. S0 U8 R9 R: ?1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu ; u, a# o" H3 v( q, n
2Department of Thoracic Surgery, Kyoto University, Kyoto - w* L7 E4 t! n4 H
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
" E: ]4 W- z! x: n&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp $ u! {" o) D8 I1 ~" D  q
Received September 3, 2010. " o7 e" w3 f* K, A
Revision received November 11, 2010.
) J, \; A" \( ]  Q, S+ y7 K; sAccepted November 17, 2010. $ U. n" E) ~9 m' V- V
Abstract" K/ I* V; r* e$ e1 i& e
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. # F% W/ x  m4 w% ?4 d6 z  h' D
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
! f7 ?3 y# _( o6 s; X  RResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 3 i4 x, p" g3 K; L, A4 a/ Q
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ( Q$ S/ [- G1 ^# `) H6 i: q, m
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
3 \6 b& s( A2 a5 w% Y6 ~+ @今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?" w' S5 |  {0 H
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
1 P5 @7 q1 n% D- U4 e7 M0 O& Q* Shttp://clinicaltrials.gov/ct2/show/NCT01523587
* B9 {4 }+ d, t, R$ ^& G2 C0 p9 W: @! d; ?
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
+ R0 v7 m) _5 @3 V! |http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 8 f' e2 X7 w- C6 P6 H' R) E

' N% c4 G# K, |& ^% ^% r2 B从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 s& ~$ a, j/ L/ m* s
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

& _7 f; _5 h7 {$ T7 h, i% P没有副作用是第一追求,效果显著是第二追求。7 W- H2 ?; \7 P3 f6 ?( d
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表